Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Screening of CACNA1A and ATP1A2 genes in hemiplegic migraine: clinical, genetic, and functional studies

  • Carreño, Oriel
  • Corominas, Roser
  • Serra Pascual, Selma A., 1981-
  • Sintas, Cèlia
  • Fernández Castillo, Noelia
  • Vila Pueyo, Marta
  • Toma, Claudio
  • Gené, Gemma
  • Pons, Roser
  • Llaneza, Miguel
  • Sobrido, María Jesús
  • Grinberg, Daniel
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Fernández-Fernández, José Manuel, 1967-
  • Macaya, Alfons
  • Cormand, Bru
Hemiplegic migraine (HM) is a rare and severe subtype of autosomal dominant migraine, characterized by a complex aura including some degree of motor weakness. Mutations in four genes (CACNA1A, ATP1A2, SCN1A and PRRT2) have been detected in familial and in sporadic cases. This genetically and clinically heterogeneous disorder is often accompanied by permanent ataxia, epileptic seizures, mental retardation, and chronic progressive cerebellar atrophy. Here we report a mutation screening in the CACNA1A and ATP1A2 genes in 18 patients with HM. Furthermore, intragenic copy number variant (CNV) analysis was performed in CACNA1A using quantitative approaches. We identified four previously described missense CACNA1A mutations (p.Ser218Leu, p.Thr501Met, p.Arg583Gln, and p.Thr666Met) and two missense changes in the ATP1A2 gene, the previously described p.Ala606Thr and the novel variant p.Glu825Lys. No structural variants were found. This genetic screening allowed the identification of more than 30% of the disease alleles, all present in a heterozygous state. Functional consequences of the CACNA1A-p.Thr501Met mutation, previously described only in association with episodic ataxia, and ATP1A2-p.Glu825Lys, were investigated by means of electrophysiological studies, cell viability assays or Western blot analysis. Our data suggest that both these variants are disease-causing., The work was funded by the Spanish Ministry of Science and Innovation, the Spanish Ministry of Economy and Competitiveness,Fondos Europeos de Desarrollo Regional (FEDER) and Plan E (Grants SAF2012 -31089, SAF2012-3814 0, BES-2010-033895, SAF2009-13182-C03-01, SAF2009-13182-C03-02, and SAF2009-13182-C03-03), Fondo de Investigación Sanitaria (Cardiovascular Disease Network RD12/0042/0014) and Generalitat de Catalunya (grants 2009SGR0971, 2009SGR0078 and 2009SGR1369). M. A. V. and N. F.-C. are the recipients of an ICREA Academia Award (Generalitat de Catalunya) and a grant from “CIBER-ER,” respectively. C. T. was supported by the European Union (Marie Curie, PIEF-GA-2009-254930).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Mutation Spectrum in the CACNA1A Gene in 49 Patients with Episodic Ataxia

  • Sintas, Cèlia
  • Carreño, Oriel
  • Fernández Castillo, Noelia
  • Corominas, Roser
  • Vila Pueyo, Marta
  • Toma, Claudio
  • Cuenca-León, Ester
  • Barroeta, Isabel
  • Roig, Carles
  • Volpini, Victor
  • Macaya, Alfons
  • Cormand, Bru
Episodic ataxia is an autosomal dominant ion channel disorder characterized by episodes of imbalance and incoordination. The disease is genetically heterogeneous and is classified as episodic ataxia type 2 (EA2) when it is caused by a mutation in the CACNA1A gene, encoding the α1A subunit of the P/Q-type voltage-gated calcium channel Cav2.1. The vast majority of EA2 disease-causing variants are loss-of-function (LoF) point changes leading to decreased channel currents. CACNA1A exonic deletions have also been reported in EA2 using quantitative approaches. We performed a mutational screening of the CACNA1A gene, including the promoter and 3'UTR regions, in 49 unrelated patients diagnosed with episodic ataxia. When pathogenic variants were not found by sequencing, we performed a copy number variant (CNV) analysis to screen for duplications or deletions. Overall, sequencing screening allowed identification of six different point variants (three nonsense and three missense changes) and two coding indels, one of them found in two unrelated patients. Additionally, CNV analysis identified a deletion in a patient spanning exon 35 as a result of a recombination event between flanking intronic Alu sequences. This study allowed identification of potentially pathogenic alterations in our sample, five of them novel, which cover 20% of the patients (10/49). Our data suggest that most of these variants are disease-causing, although functional studies are required., The funding for this study was provided by the Spanish Ministerio de Economía y Competitividad (SAF2009-13182-C01, SAF2009-13182-C03), AGAUR (2014SGR-0932, 2009SGR-0078) and Fundació La Marató de TV3 (grant 100731). These institutions had no further role in study design, collection, analysis, interpretation of data or in the submission of this paper for publication. CS and OC were supported by Ministerio de Economía y Competitividad (BES-2007-16450 and BES-2010-033895, respectively) and NF-C by Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER, ISCIII). MV-P was supported by a predoctoral grant from VHIR, Barcelona (Spain). CT was supported by the European Union (Marie Curie, PIEF-GA-2009-254930). EC-L is the recipient of the Beatriu de Pinós programme scholarship (BP-DGR 2010).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Chiari malformation type I: a case-control association study of 58 developmental genes

  • Urbizu Serrano, Aintzane
  • Toma, Claudio
  • Poca Pastor, María Antonia
  • Sahuquillo, Juan
  • Cuenca León, Ester
  • Cormand Rifà, Bru
  • Macaya Ruiz, Alfons
Chiari malformation type I (CMI) is a disorder characterized by hindbrain overcrowding into an underdeveloped posterior cranial fossa (PCF), often causing progressive neurological symptoms. The etiology of CMI remains unclear and is most likely multifactorial. A putative genetic contribution to CMI is suggested by familial aggregation and twin studies. Experimental models and human morphometric studies have suggested an underlying paraxial mesoderm insufficiency. We performed a case-control association study of 303 tag single nucleotide polymorphisms (SNP) across 58 candidate genes involved in early paraxial mesoderm development in a sample of 415 CMI patients and 524 sex-matched controls. A subgroup of patients diagnosed with classical, small-PCF CMI by means of MRI-based PCF morphometry (n = 186), underwent additional analysis. The genes selected are involved in signalling gradients occurring during segmental patterning of the occipital somites (FGF8, Wnt, and retinoic acid pathways and from bone morphogenetic proteins or BMP, Notch, Cdx and Hox pathways) or in placental angiogenesis, sclerotome development or CMI-associated syndromes. Single-marker analysis identified nominal associations with 18 SNPs in 14 genes (CDX1, FLT1, RARG, NKD2, MSGN1, RBPJ1, FGFR1, RDH10, NOG, RARA, LFNG, KDR, ALDH1A2, BMPR1A) considering the whole CMI sample. None of these overcame corrections for multiple comparisons, in contrast with four SNPs in CDX1, FLT1 and ALDH1A2 in the classical CMI group. Multiple marker analysis identified a risk haplotype for classical CMI in ALDH1A2 and CDX1. Furthermore, we analyzed the possible contributions of the most significantly associated SNPs to different PCF morphometric traits. These findings suggest that common variants in genes involved in somitogenesis and fetal vascular development may confer susceptibility to CMI.
Dipòsit Digital de la UB
Publicación Tesis doctoral (DoctoralThesis)

Aspectes moleculars de dues malalties de transport lisosòmic: la cistinosi i la malaltia de Niemann-Pick tipus C

  • Macías Vidal, Judit
[cat] La cistinosi i la malaltia de Niemann-Pick tipus C (NPC) són dues patologies hereditàries monogèniques poc freqüents, per aquest motiu estan classificades dins del grup de malalties anomenades rares. La cistinosi està causada per mutacions al gen CTNS, que codifica per una proteïna transmembrana del lisosoma que rep el nom de cistinosina. En canvi, la malaltia de NPC és deguda a mutacions al gen NPC1 o al gen NPC2, que codifiquen per una proteïna integral de la membrana lisosòmica i una proteïna soluble del lisosoma, respectivament, i aquestes reben el mateix nom que el gen, NPC1 i NPC2. El funcionament incorrecte d’aquestes proteïnes de transport dóna lloc a una acumulació de productes, diferent a ambdós casos, a l’interior del lisosoma, sent classificades com a malalties d’acumulació lisosòmica. Aquesta tesi doctoral s’ha centrat en l’anàlisi molecular de pacients afectes d’alguna d’aquestes dues malalties. S’ha realitzat el primer estudi mutacional de cistinosi a la població espanyola, que ha permès la identificació de 15 mutacions diferents, 7 de les quals no havien estat descrites: tres mutacions de canvi de sentit (p.M1T, p.S270F i p.G309V), tres delecions (c.1-19_61del, c.295_310del i c.320_323delATCA) i una mutació de splicing (c.682-1G>T). La deleció de 57 kb és la mutació més freqüent a Espanya (38% dels al•lels) i conjuntament amb altres 5 mutacions representen el 73% dels al•lels estudiats. S’ha establert que els pacients amb fenotip clínic infantil tenen a ambdós al•lels mutacions que trunquen o que afecten aminoàcids conservats de les regions transmembrana de la proteïna. En canvi, la mutació p.S139F s’ha associat a la forma juvenil de la malaltia. L’estudi mutacional realitzat a la malaltia de Niemann-Pick tipus C ha permès establir el genotip d’un gran nombre de pacients, identificant 74 mutacions diferents, 17 de les quals no havien estat descrites: set mutacions de canvi de sentit (p.P474A, p.G535V, p.F995L, p.F1079S, p.L1106P, p.G1209E i p.S1249G), dues mutacions sense sentit (p.Q775X i p.E1089X), dues insercions (p.L1117PfsX4 i p.I1061NfsX4), una deleció en pauta (p.N916del), quatre mutacions de splicing (c.58-3280C>G, c.882-28A>T, c.2604+5G>A i c.3591+5G>A) i la primera gran deleció que afecta al gen NPC1 i gens flanquejants. També s’han pogut establir correlacions genotip-fenotip per a un conjunt de mutacions. També s’ha demostrat la implicació de diferents mecanismes cel•lulars en la malaltia de Niemann-Pick tipus C, segons els tipus de mutacions causants: el “splicing”, el procés de “nonsense-mediated mRNA decay” i la degradació proteica portada a terme pel proteasoma. S’han identificat mutacions intròniques profundes i s’ha caracteritzat el seu efecte en el mRNA, conjuntament amb el de les mutacions de “splicing” que afecten als llocs canònics. El mecanisme de NMD és el responsable de la degradació del mRNA en tots els al•lels analitzats que codifiquen per un PTC al gen NPC1. La majoria de mutacions de canvi de sentit analitzades condueixen a una reducció significativa o a l’absència de la proteïna NPC1, degut a què la proteïna NPC1 mutada és degradada per la via de la ubiquitina-proteasoma. La proteïna NPC1 mutada recuperada, després del tractament amb els inhibidors del proteasoma (ALLN i MG132), és capaç de disminuir els nivells de colesterol a totes les línies cel•lulars NPC estudiades. Aquesta observació podria obrir la porta a l’ús d’aquests fàrmacs com a futur tractament per a la malaltia de NPC causada per determinades mutacions de canvi de sentit., [eng] “Molecular aspects of both lysosomal transport diseases: cystinosis and Niemann-Pick disease type”. The cystinosis and Niemann-Pick disease type C (NPC) are two rare monogenic hereditary diseases. The cystinosis is caused by mutations in the gene CTNS, which encodes a transmembrane protein of the lysosome that is called cystinosin. NPC disease is caused by mutations in the NPC1 or NPC2 gene, encoding an integral lysosomal membrane protein and a soluble protein of the lysosome, respectively, and these are the same name as the gene, NPC1 and NPC2. The impaired transport leads to an accumulation of products, different in both cases, inside the lysosome, being classified as lysosomal storage disorders. This thesis has focused on the molecular analysis of patients with any of these diseases. Molecular analysis in the Spanish cystinosis patients has allowed the identification of 15 different mutations, 7 of which had not been described. The 57-kb deletion is the most common mutation in Spain (38% of alleles) and together with other 5 mutations accounted for 73% of the studied alleles. The p.S139F mutation has been associated with the juvenile form of the disease. Molecular analysis in NPC disease has established the mutation profile in a large number of patients. 74 different mutations have been identified, 17 of which had not been described previously, including the first large deletion affecting the whole NPC1 gene and flanking genes. Genotype-phenotype correlations have been established for several mutations. Different cellular mechanisms are involving in NPC disease: splicing, nonsense-mediated mRNA decay and proteasomal degradation. Deep intronic mutations have been identified and the effect on the mRNA has been characterized. NMD process is responsible for the mRNA decay for all analyzed NPC1 PTC-encoding mutations. Several missense mutations lead to a significant reduction or absence of NPC1 protein, because the NPC1 mutant protein is degraded by the ubiquitin-proteasome pathway. Treatment with proteasome inhibitors partially reverses the NPC1 decrease and reduces cholesterol levels in all studied NPC cell lines. This observation might represent a therapeutical approach for future treatments of NPC disease caused by specific missense mutations.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Mutation spectrum in the CACNA1A gene in 49 patients with episodic ataxia

  • Sintas Vives, Cèlia
  • Carreño, Oriel
  • Fernàndez Castillo, Noèlia
  • Corominas Castiñeira, Roser
  • Vila Pueyo, Marta
  • Toma, Claudio
  • Cuenca León, Ester
  • Barroeta, Isabel
  • Roig i Arnall, Carles
  • Volpini Bertrán, Víctor
  • Macaya Ruiz, Alfons
  • Cormand Rifà, Bru
Episodic ataxia is an autosomal dominant ion channel disorder characterized by episodes of imbalance and incoordination. The disease is genetically heterogeneous and is classified as episodic ataxia type 2 (EA2) when it is caused by a mutation in the CACNA1A gene, encoding the α1A subunit of the P/Q-type voltage-gated calcium channel Cav2.1. The vast majority of EA2 disease-causing variants are loss-of-function (LoF) point changes leading to decreased channel currents. CACNA1A exonic deletions have also been reported in EA2 using quantitative approaches. We performed a mutational screening of the CACNA1A gene, including the promoter and 3′UTR regions, in 49 unrelated patients diagnosed with episodic ataxia. When pathogenic variants were not found by sequencing, we performed a copy number variant (CNV) analysis to screen for duplications or deletions. Overall, sequencing screening allowed identification of six different point variants (three nonsense and three missense changes) and two coding indels, one of them found in two unrelated patients. Additionally, CNV analysis identified a deletion in a patient spanning exon 35 as a result of a recombination event between flanking intronic Alu sequences. This study allowed identification of potentially pathogenic alterations in our sample, five of them novel, which cover 20% of the patients (10/49). Our data suggest that most of these variants are disease-causing, although functional studies are required.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Screening of CACNA1A and ATP1A2 genes in hemiplegic migraine: clinical, genetic and functional studies

  • Carreño, Oriel
  • Corominas Castiñeira, Roser
  • Serra, Selma Angèlica
  • Sintas Vives, Cèlia
  • Fernàndez Castillo, Noèlia
  • Vila Pueyo, Marta
  • Toma, Claudio
  • González Gené, Gemma
  • Pons, Roser
  • Llaneza, Miguel
  • Sobrido, María Jesús
  • Grinberg Vaisman, Daniel Raúl
  • Valverde, Miguel Ángel
  • Fernández-Fernández, José Manuel
  • Macaya Ruiz, Alfons
  • Cormand Rifà, Bru
Hemiplegic migraine (HM) is a rare and severe subtype of autosomal dominant migraine, characterized by a complex aura including some degree of motor weakness. Mutations in four genes (CACNA1A, ATP1A2, SCN1A and PRRT2) have been detected in familial and in sporadic cases. This genetically and clinically heterogeneous disorder is often accompanied by permanent ataxia, epileptic seizures, mental retardation, and chronic progressive cerebellar atrophy. Here we report a mutation screening in the CACNA1A and ATP1A2 genes in 18 patients with HM. Furthermore, intragenic copy number variant (CNV) analysis was performed in CACNA1A using quantitative approaches. We identified four previously described missense CACNA1A mutations (p.Ser218Leu, p.Thr501Met, p.Arg583Gln, and p.Thr666Met) and two missense changes in the ATP1A2 gene, the previously described p.Ala606Thr and the novel variant p.Glu825Lys. No structural variants were found. This genetic screening allowed the identification of more than 30% of the disease alleles, all present in a heterozygous state. Functional consequences of the CACNA1A-p.Thr501Met mutation, previously described only in association with episodic ataxia, and ATP1A2-p.Glu825Lys, were investigated by means of electrophysiological studies, cell viability assays or Western blot analysis. Our data suggest that both these variants are disease-causing.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Screening of CACNA1A and ATP1A2 genes in hemiplegic migraine: clinical, genetic and functional studies

  • Carreño, Oriel
  • Corominas Castiñeira, Roser
  • Serra, Selma Angèlica
  • Sintas Vives, Cèlia
  • Fernàndez Castillo, Noèlia
  • Vila Pueyo, Marta
  • Toma, Claudio
  • González Gené, Gemma
  • Pons, Roser
  • Llaneza, Miguel
  • Sobrido, María Jesús
  • Grinberg Vaisman, Daniel Raúl
  • Valverde, Miguel Ángel
  • Fernández-Fernández, José Manuel
  • Macaya Ruiz, Alfons
  • Cormand Rifà, Bru
Hemiplegic migraine (HM) is a rare and severe subtype of autosomal dominant migraine, characterized by a complex aura including some degree of motor weakness. Mutations in four genes (CACNA1A, ATP1A2, SCN1A and PRRT2) have been detected in familial and in sporadic cases. This genetically and clinically heterogeneous disorder is often accompanied by permanent ataxia, epileptic seizures, mental retardation, and chronic progressive cerebellar atrophy. Here we report a mutation screening in the CACNA1A and ATP1A2 genes in 18 patients with HM. Furthermore, intragenic copy number variant (CNV) analysis was performed in CACNA1A using quantitative approaches. We identified four previously described missense CACNA1A mutations (p.Ser218Leu, p.Thr501Met, p.Arg583Gln, and p.Thr666Met) and two missense changes in the ATP1A2 gene, the previously described p.Ala606Thr and the novel variant p.Glu825Lys. No structural variants were found. This genetic screening allowed the identification of more than 30% of the disease alleles, all present in a heterozygous state. Functional consequences of the CACNA1A-p.Thr501Met mutation, previously described only in association with episodic ataxia, and ATP1A2-p.Glu825Lys, were investigated by means of electrophysiological studies, cell viability assays or Western blot analysis. Our data suggest that both these variants are disease-causing.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Screening of CACNA1A and ATP1A2 genes in hemiplegic migraine: clinical, genetic, and functional studies

  • Carreño, Oriel
  • Corominas, Roser
  • Serra Pascual, Selma A., 1981-
  • Sintas, Cèlia
  • Fernández Castillo, Noelia
  • Vila Pueyo, Marta
  • Toma, Claudio
  • Gené, Gemma
  • Pons, Roser
  • Llaneza, Miguel
  • Sobrido, María Jesús
  • Grinberg, Daniel
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Fernández-Fernández, José Manuel, 1967-
  • Macaya, Alfons
  • Cormand, Bru
Hemiplegic migraine (HM) is a rare and severe subtype of autosomal dominant migraine, characterized by a complex aura including some degree of motor weakness. Mutations in four genes (CACNA1A, ATP1A2, SCN1A and PRRT2) have been detected in familial and in sporadic cases. This genetically and clinically heterogeneous disorder is often accompanied by permanent ataxia, epileptic seizures, mental retardation, and chronic progressive cerebellar atrophy. Here we report a mutation screening in the CACNA1A and ATP1A2 genes in 18 patients with HM. Furthermore, intragenic copy number variant (CNV) analysis was performed in CACNA1A using quantitative approaches. We identified four previously described missense CACNA1A mutations (p.Ser218Leu, p.Thr501Met, p.Arg583Gln, and p.Thr666Met) and two missense changes in the ATP1A2 gene, the previously described p.Ala606Thr and the novel variant p.Glu825Lys. No structural variants were found. This genetic screening allowed the identification of more than 30% of the disease alleles, all present in a heterozygous state. Functional consequences of the CACNA1A-p.Thr501Met mutation, previously described only in association with episodic ataxia, and ATP1A2-p.Glu825Lys, were investigated by means of electrophysiological studies, cell viability assays or Western blot analysis. Our data suggest that both these variants are disease-causing., The work was funded by the Spanish Ministry of Science and Innovation, the Spanish Ministry of Economy and Competitiveness,Fondos Europeos de Desarrollo Regional (FEDER) and Plan E (Grants SAF2012 -31089, SAF2012-3814 0, BES-2010-033895, SAF2009-13182-C03-01, SAF2009-13182-C03-02, and SAF2009-13182-C03-03), Fondo de Investigación Sanitaria (Cardiovascular Disease Network RD12/0042/0014) and Generalitat de Catalunya (grants 2009SGR0971, 2009SGR0078 and 2009SGR1369). M. A. V. and N. F.-C. are the recipients of an ICREA Academia Award (Generalitat de Catalunya) and a grant from “CIBER-ER,” respectively. C. T. was supported by the European Union (Marie Curie, PIEF-GA-2009-254930).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mutation spectrum in the CACNA1A gene in 49 patients with episodic ataxia

  • Sintas Vives, Cèlia
  • Carreño, Oriel
  • Fernàndez Castillo, Noèlia
  • Corominas Castiñeira, Roser
  • Vila Pueyo, Marta
  • Toma, Claudio
  • Cuenca León, Ester
  • Barroeta, Isabel
  • Roig i Arnall, Carles
  • Volpini Bertrán, Víctor
  • Macaya Ruiz, Alfons
  • Cormand Rifà, Bru
Episodic ataxia is an autosomal dominant ion channel disorder characterized by episodes of imbalance and incoordination. The disease is genetically heterogeneous and is classified as episodic ataxia type 2 (EA2) when it is caused by a mutation in the CACNA1A gene, encoding the α1A subunit of the P/Q-type voltage-gated calcium channel Cav2.1. The vast majority of EA2 disease-causing variants are loss-of-function (LoF) point changes leading to decreased channel currents. CACNA1A exonic deletions have also been reported in EA2 using quantitative approaches. We performed a mutational screening of the CACNA1A gene, including the promoter and 3′UTR regions, in 49 unrelated patients diagnosed with episodic ataxia. When pathogenic variants were not found by sequencing, we performed a copy number variant (CNV) analysis to screen for duplications or deletions. Overall, sequencing screening allowed identification of six different point variants (three nonsense and three missense changes) and two coding indels, one of them found in two unrelated patients. Additionally, CNV analysis identified a deletion in a patient spanning exon 35 as a result of a recombination event between flanking intronic Alu sequences. This study allowed identification of potentially pathogenic alterations in our sample, five of them novel, which cover 20% of the patients (10/49). Our data suggest that most of these variants are disease-causing, although functional studies are required.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mutation Spectrum in the CACNA1A Gene in 49 Patients with Episodic Ataxia

  • Sintas, Cèlia
  • Carreño, Oriel
  • Fernández Castillo, Noelia
  • Corominas, Roser
  • Vila Pueyo, Marta
  • Toma, Claudio
  • Cuenca-León, Ester
  • Barroeta, Isabel
  • Roig, Carles
  • Volpini, Victor
  • Macaya, Alfons
  • Cormand, Bru
Episodic ataxia is an autosomal dominant ion channel disorder characterized by episodes of imbalance and incoordination. The disease is genetically heterogeneous and is classified as episodic ataxia type 2 (EA2) when it is caused by a mutation in the CACNA1A gene, encoding the α1A subunit of the P/Q-type voltage-gated calcium channel Cav2.1. The vast majority of EA2 disease-causing variants are loss-of-function (LoF) point changes leading to decreased channel currents. CACNA1A exonic deletions have also been reported in EA2 using quantitative approaches. We performed a mutational screening of the CACNA1A gene, including the promoter and 3'UTR regions, in 49 unrelated patients diagnosed with episodic ataxia. When pathogenic variants were not found by sequencing, we performed a copy number variant (CNV) analysis to screen for duplications or deletions. Overall, sequencing screening allowed identification of six different point variants (three nonsense and three missense changes) and two coding indels, one of them found in two unrelated patients. Additionally, CNV analysis identified a deletion in a patient spanning exon 35 as a result of a recombination event between flanking intronic Alu sequences. This study allowed identification of potentially pathogenic alterations in our sample, five of them novel, which cover 20% of the patients (10/49). Our data suggest that most of these variants are disease-causing, although functional studies are required., The funding for this study was provided by the Spanish Ministerio de Economía y Competitividad (SAF2009-13182-C01, SAF2009-13182-C03), AGAUR (2014SGR-0932, 2009SGR-0078) and Fundació La Marató de TV3 (grant 100731). These institutions had no further role in study design, collection, analysis, interpretation of data or in the submission of this paper for publication. CS and OC were supported by Ministerio de Economía y Competitividad (BES-2007-16450 and BES-2010-033895, respectively) and NF-C by Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER, ISCIII). MV-P was supported by a predoctoral grant from VHIR, Barcelona (Spain). CT was supported by the European Union (Marie Curie, PIEF-GA-2009-254930). EC-L is the recipient of the Beatriu de Pinós programme scholarship (BP-DGR 2010).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Chiari malformation type I: a case-control association study of 58 developmental genes

  • Urbizu Serrano, Aintzane
  • Toma, Claudio
  • Poca Pastor, María Antonia
  • Sahuquillo, Juan
  • Cuenca León, Ester
  • Cormand Rifà, Bru
  • Macaya Ruiz, Alfons
Chiari malformation type I (CMI) is a disorder characterized by hindbrain overcrowding into an underdeveloped posterior cranial fossa (PCF), often causing progressive neurological symptoms. The etiology of CMI remains unclear and is most likely multifactorial. A putative genetic contribution to CMI is suggested by familial aggregation and twin studies. Experimental models and human morphometric studies have suggested an underlying paraxial mesoderm insufficiency. We performed a case-control association study of 303 tag single nucleotide polymorphisms (SNP) across 58 candidate genes involved in early paraxial mesoderm development in a sample of 415 CMI patients and 524 sex-matched controls. A subgroup of patients diagnosed with classical, small-PCF CMI by means of MRI-based PCF morphometry (n = 186), underwent additional analysis. The genes selected are involved in signalling gradients occurring during segmental patterning of the occipital somites (FGF8, Wnt, and retinoic acid pathways and from bone morphogenetic proteins or BMP, Notch, Cdx and Hox pathways) or in placental angiogenesis, sclerotome development or CMI-associated syndromes. Single-marker analysis identified nominal associations with 18 SNPs in 14 genes (CDX1, FLT1, RARG, NKD2, MSGN1, RBPJ1, FGFR1, RDH10, NOG, RARA, LFNG, KDR, ALDH1A2, BMPR1A) considering the whole CMI sample. None of these overcame corrections for multiple comparisons, in contrast with four SNPs in CDX1, FLT1 and ALDH1A2 in the classical CMI group. Multiple marker analysis identified a risk haplotype for classical CMI in ALDH1A2 and CDX1. Furthermore, we analyzed the possible contributions of the most significantly associated SNPs to different PCF morphometric traits. These findings suggest that common variants in genes involved in somitogenesis and fetal vascular development may confer susceptibility to CMI.